Natus Medical Incorporated (NASDAQ:BABY) shares fell 0.4% on Wednesday following insider selling activity. The company traded as low as $38.30 and last traded at $40.85. 500,700 shares were traded during mid-day trading, an increase of 29% from the average session volume of 386,740 shares. The stock had previously closed at $41.00.

Specifically, Director William M. Moore sold 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. In the last three months, insiders sold 22,042 shares of company stock valued at $902,266. Company insiders own 5.50% of the company’s stock.

BABY has been the subject of several research analyst reports. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Tuesday, October 24th. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Natus Medical has an average rating of “Hold” and a consensus price target of $46.50.

The company has a current ratio of 4.21, a quick ratio of 3.36 and a debt-to-equity ratio of 0.36. The firm has a market cap of $1,180.00, a price-to-earnings ratio of 26.35 and a beta of 0.89.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million during the quarter, compared to analyst estimates of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The company’s revenue was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.39 earnings per share. research analysts predict that Natus Medical Incorporated will post 1.74 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in BABY. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Natus Medical by 2,085.6% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 2,607 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in shares of Natus Medical by 90.9% during the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 1,364 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Natus Medical by 29.7% during the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after purchasing an additional 728 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Natus Medical during the third quarter valued at $138,000. Finally, Victory Capital Management Inc. lifted its holdings in shares of Natus Medical by 17.6% during the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after purchasing an additional 560 shares during the last quarter. 99.53% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Natus Medical Incorporated (BABY) Trading Down 0.4% After Insider Selling” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/natus-medical-incorporated-baby-trading-down-0-4-after-insider-selling/1708384.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.